What Is the Best Time to Take Antihypertensives?

Bedtime hypertensive therapy might reduce the risk of cardiovascular events according to this study soon to be published in Eur Heart J. However, despite showing significant risk reduction this hypothesis calls for further study before radically changing the usual upon awakening therapy. 

¿Cuál es el mejor momento del día para administrar antihipertensivos?

Taking the prescribed medication before bedtime could allow our bodies to naturally follow its circadian rhythms, boosting medication effect, improving blood pressure control and, ultimately, reducing cardiovascular events. 

This study is, without question, the largest to assess blood pressure medication time intake and the one with longest follow-up. It was carried out in several primary healthcare centers and, therefore, should reflect the daily practice. 

The Hygia Chronotherapy Trial randomized over 19000 hypertensive patients to taking medication upon awakening (angiotensin blockers, angiotensin converting enzyme inhibitors, calcium blockers, beta blockers and/or diuretics) vs. at bedtime. 


Read also: Prosthesis Mismatch in Supra and Intra Annular valves.


After a mean 6.3-year follow-up, patients taking their medication before going to bed had better systolic and diastolic blood pressure control.

In addition, a much smaller group of patients taking medication at bedtime qualified as “nondippers” (when blood pressure drops less than 10% while sleeping) vs. morning intake (37% vs 50%, p=0.001).

Finally, and most importantly, bedtime therapy reduced 45% primary end point risk, a composite of cardiovascular death, acute MI, coronary revascularization, cardiac failure and any stroke (p<0.001).

Some of the study data raises questions about the fact that bedtime therapy did not change daytime blood pressure readings vs. morning therapy.



Read also: Subintimal vs. Intraplaque Coronary Rechanneling. Do Results Vary?


For some experts, it seems hard to explain why reducing blood pressure while sleeping translates in such a significant reduction in events. One possible explanation, that requires validation, is that reducing blood pressure during sleep-time might have a pleiotropic effect that exceeds reduction readings per se. 

Original title: Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial.

Reference: Hermida RC et al. Eur Heart J. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...